Osseon Therapeutics has named Gary Coughlen, certified public accountant (CPA), as chief financial officer (CFO). Coughlen was most recently CFO of PolyRemedy, a private-equity medical device company focused on wound care management.
Prior to PolyRemedy, he served as the CFO of Refractec, a manufacturer, and distributor of ophthalmic surgical devices to the global market. Coughlen started in 1999 at the founder’s stage with three employees and served as Refractec’s CFO through its growth to 75 employees.
Earlier in his career, Coughlen served as CFO at Scieran Technologies and was a vice president at Sierra Capital. He began his career in the public accounting at PricewaterhouseCoopers (PwC).
Coughlen is a graduate of University of Washington, where he earned a bachelor’s degree in Business Administration and UC-Berkley where he completed his MBA.
A report by broking group Marsh examines the repercussions from the administration of the South Korean company, which filed for bankruptcy protection at the end of August.
Global research by C2FO suggests that smaller businesses are less concerned with the repercussions of Brexit and the upcoming US presidential election.
A squeeze on skilled talent means it now takes an average of seven weeks to fill open permanent roles in finance in the UK according to new research from financial services recruitment firm Robert Half.
Early-stage merger and acquisition deals in Asia-Pacific show nearly 10% year-on-year growth in recent months.